shutterstock-155405681-1

VACLAV MACH / SHUTTERSTOCK.COM

16 June 2015AmericasMichael Pears

SPCs: The semantics of protection

Combination therapies (those containing multiple active ingredients) are becoming increasingly prevalent due to factors such as public health policy, improved therapeutic effects of combining drugs, and the need to reduce the pill burden on patients.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead scores win in fake HIV drug dispute

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

AstraZeneca unit draws line under Samsung dispute

Does the UPC offer a fresh take on patent validity?

Regeneron targets almost 50 patents in suit against Sandoz

Litigation implications of the USPTO’s terminal disclaimer proposal